Welcome to our dedicated page for Addus Homecare SEC filings (Ticker: ADUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Addus HomeCare Corporation files regulatory documents that reveal how government reimbursement rates, state Medicaid budgets, and healthcare policy changes affect its three business segments. For a company where Medicaid and Medicare represent the primary revenue sources, SEC filings offer direct insight into the regulatory dynamics that shape financial performance.
The company's 10-K annual reports break down revenue by segment, showing how personal care, hospice, and home health each contribute to the business. These filings detail the states where Addus operates, payor concentration by government program, and the impact of reimbursement rate changes on margins. Healthcare investors following home-based care providers will find segment-level profitability data essential for understanding the business mix.
Quarterly 10-Q filings track how state Medicaid budget decisions flow through to revenue, particularly important given the company's dependence on government payors. These reports also show acquisition activity as Addus has historically grown through M&A, with each deal adding new service territories and payor relationships.
Form 4 insider transactions track when executives and directors buy or sell shares. For a healthcare services company operating in a heavily regulated industry, insider activity can signal management confidence around rate negotiations and policy developments.
Material event filings (8-K) capture acquisition announcements, leadership changes, and developments in key state markets. Our AI-powered summaries highlight the essential details from these filings, saving you from parsing lengthy legal disclosures to find the information that matters.
Proxy statements (DEF 14A) detail executive compensation structures, which in healthcare services often tie to patient outcomes and operational metrics alongside financial targets.
Addus HomeCare Corp. Schedule 13G reports that Capital Research Global Investors (CRGI) beneficially owns 1,102,298 shares of common stock, equal to 6.0% of the 18,399,139 shares reported outstanding. CRGI is described as a division of Capital Research and Management Company and related investment management entities and is deemed the beneficial owner through those entities. The filing states CRGI has sole voting power and sole dispositive power over all 1,102,298 shares and no shared powers. The filing certifies the securities are held in the ordinary course of business and not to influence control. SMALLCAP World Fund, Inc. is identified as an account referenced in the filing.
Wasatch Advisors LP reports beneficial ownership of 929,154 shares of Addus HomeCare common stock, representing 5.1% of the class. That level of ownership triggers Schedule 13G/A disclosure and identifies Wasatch as a material institutional holder of Addus HomeCare.
The filing states Wasatch has sole dispositive power over all 929,154 shares and sole voting power over 690,487 shares, with no shared voting or dispositive power. The document classifies Wasatch as an investment adviser organized in Delaware and includes a certification that the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control of the issuer.
Esteban Lopez, a director of Addus HomeCare (ADUS), sold 522 shares of common stock on 08/08/2025 at $109 per share. After the sale he beneficially owns 4,016 shares held directly. The filing reports only this non-derivative sale, shows no derivative holdings, and does not disclose a 10b5-1 trading plan. The Form 4 was executed by an attorney-in-fact.
Addus HomeCare (ADUS) filed a Form 144 reporting a proposed resale of 522 common shares through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $56,898 and 18,407,239 shares outstanding. The filing lists an approximate sale date of 08/08/2025.
The securities were acquired as restricted stock from the issuer on 06/12/2025 with payment recorded the same day, and the filer reports "Nothing to Report" for sales in the past three months. This Form 144 is a notice of intended resale under Rule 144 and includes the seller's representation that they are not aware of any undisclosed material adverse information.
Addus HomeCare Corporation (ADUS) reported the voting results from its 18 June 2025 Annual Meeting of Stockholders in an 8-K filing (Item 5.07).
- Quorum: 17,431,919 shares (94.7% of the 18,399,139 shares outstanding) were represented.
- Director elections: Class I nominees Esteban López, M.D. (93.2% support), Jean Rush (95.2% support) and Susan T. Weaver, M.D. (91.5% support) were elected for terms expiring in 2028. Broker non-votes totaled 875,876 for each nominee.
- Auditor ratification: PricewaterhouseCoopers LLP was re-appointed with 17,369,357 votes for (99.7%), 59,873 against and 2,689 abstentions.
- Say-on-Pay: Executive compensation received 15,216,859 votes for (92.0%), 1,330,522 against and 8,662 abstentions.
- Say-on-Pay frequency: An annual vote was favored by 15,903,154 shares (92.9%), compared with 632,362 for triennial, 3,984 for biennial and 16,543 abstentions. No broker non-votes.
- Board response: The Board will continue to hold the advisory Say-on-Pay vote annually until the next required frequency vote.
The filing contains no financial performance data, strategic transactions or changes to previously reported guidance. All proposals were approved by wide margins, indicating solid shareholder support for governance, compensation and audit practices.
Form 4 filing – Addus HomeCare Corp. (ADUS)
Non-employee director Jean Rush reported the grant of 1,172 shares of restricted common stock on 06/18/2025. The award was received at $0 cost and is scheduled to vest in full on 06/18/2026. Following the transaction, Rush’s direct beneficial ownership stands at 9,221 shares. No derivative securities were created or disposed of, and there were no share sales.
The transaction appears to be a routine component of director equity compensation designed to align board and shareholder interests. The filing, signed by attorney-in-fact Brian Poff on 06/20/2025, does not reference a Rule 10b5-1 trading plan.
Form 4 filing overview – Addus HomeCare Corp. (ADUS)
Director Darin J. Gordon reported the grant of 1,172 restricted common shares on 18-Jun-2025. The award was received at $0 cost under a standard non-employee director compensation plan and will vest in full on 18-Jun-2026. Following the grant, Gordon’s direct ownership rises to 12,795 ADUS shares.
No derivative securities were reported, and there were no sales or open-market purchases. The filing represents routine equity compensation intended to align the director’s interests with shareholders and does not signal a change in company fundamentals.
FAQ
What is the current stock price of Addus Homecare (ADUS)?
What is the market cap of Addus Homecare (ADUS)?
